These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 30394883

  • 1. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL, Garajová I, Caparello C, Le Large TYS, Frampton AE, Vasile E, Funel N, Kazemier G, Giovannetti E.
    Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
    [Abstract] [Full Text] [Related]

  • 2. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG.
    JAMA Surg; 2020 Sep 01; 155(9):832-839. PubMed ID: 32667641
    [Abstract] [Full Text] [Related]

  • 3. Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study.
    van der Sijde F, Homs MYV, van Bekkum ML, van den Bosch TPP, Bosscha K, Besselink MG, Bonsing BA, de Groot JWB, Karsten TM, Groot Koerkamp B, Haberkorn BCM, Luelmo SAC, Mekenkamp LJM, Mustafa DAM, Wilmink JW, van Eijck CHJ, Vietsch EE, On Behalf Of The Dutch Pancreatic Cancer Group.
    Int J Mol Sci; 2021 Oct 09; 22(20):. PubMed ID: 34681562
    [Abstract] [Full Text] [Related]

  • 4. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR.
    Ann Surg; 2019 Apr 09; 269(4):733-740. PubMed ID: 29227344
    [Abstract] [Full Text] [Related]

  • 5. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
    Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, Moik F, Barth DA, Rossmann CH, Stotz M, Schaberl-Moser R, Pichler M, Stöger H, Greil R, Djanani A, Schlick K, Gerger A.
    Eur J Cancer; 2021 Jul 09; 151():3-13. PubMed ID: 33951545
    [Abstract] [Full Text] [Related]

  • 6. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Nichetti F, Rota S, Ambrosini P, Pircher C, Gusmaroli E, Droz Dit Busset M, Pusceddu S, Sposito C, Coppa J, Morano F, Pietrantonio F, Di Bartolomeo M, Mariani L, Mazzaferro V, de Braud F, Niger M.
    JAMA Netw Open; 2024 Jan 02; 7(1):e2350756. PubMed ID: 38190183
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, Schrag D, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C.
    Oncologist; 2019 Jul 02; 24(7):945-954. PubMed ID: 30559125
    [Abstract] [Full Text] [Related]

  • 8. FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines.
    Begg SKS, Birnbaum DJ, Clark JW, Mino-Kenudson M, Wellner UF, Schilling O, Lillemoe KD, Warshaw AL, Castillo CF, Liss AS.
    Anticancer Res; 2020 Jul 02; 40(7):3659-3667. PubMed ID: 32620605
    [Abstract] [Full Text] [Related]

  • 9. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
    McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O'Reilly EM, Varghese AM, Yu KH, Balachandran VP, Soares KC, D'Angelica MI, Drebin JA, Kingham TP, Allen PJ, Wei AC, Jarnagin WR.
    J Surg Oncol; 2022 Mar 02; 125(3):425-436. PubMed ID: 34719035
    [Abstract] [Full Text] [Related]

  • 10. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort.
    Lansbergen MF, Dings MPG, Manoukian P, Fariña A, Waasdorp C, Hooijer GKJ, Verheij J, Koster J, Zwijnenburg DA, Wilmink JW, Medema JP, Dijk F, van Laarhoven HWM, Bijlsma MF.
    Transl Res; 2024 Nov 02; 273():137-147. PubMed ID: 39154856
    [Abstract] [Full Text] [Related]

  • 11. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A.
    Eur J Cancer; 2021 Jul 02; 151():14-24. PubMed ID: 33957442
    [Abstract] [Full Text] [Related]

  • 12. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
    Raphael MJ, Raskin W, Habbous S, Tai X, Beca J, Dai WF, Arias J, Forbes L, Gavura S, Biagi JJ, Earle CC, Chan KKW.
    JAMA Netw Open; 2021 Nov 01; 4(11):e2133388. PubMed ID: 34779846
    [Abstract] [Full Text] [Related]

  • 13. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V, König A, Seufferlein T.
    Digestion; 2016 Nov 01; 94(1):44-9. PubMed ID: 27438590
    [Abstract] [Full Text] [Related]

  • 14. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
    Yamamoto KN, Nakamura A, Liu LL, Stein S, Tramontano AC, Kartoun U, Shimizu T, Inoue Y, Asakuma M, Haeno H, Kong CY, Uchiyama K, Gonen M, Hur C, Michor F.
    PLoS One; 2019 Nov 01; 14(4):e0215409. PubMed ID: 31026288
    [Abstract] [Full Text] [Related]

  • 15. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A, Lee M, Le H, Wilson K, Aiken C, Chantrill L, Simes J, Nguyen N, Barbour A, Samra J, Sjoquist KM, Moore A, Espinoza D, Gebski V, Yip S, Chu J, Kneebone A, Goldstein D.
    BMC Cancer; 2021 Aug 19; 21(1):936. PubMed ID: 34412605
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence.
    Gupta A, De Jesus-Acosta A, Le D, Pishvaian M, Zaidi N, Zheng L, Laheru D.
    Cancer; 2024 Nov 01; 130(21):3734-3744. PubMed ID: 38985839
    [Abstract] [Full Text] [Related]

  • 17. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
    Latenstein AEJ, Mackay TM, Creemers GJ, van Eijck CHJ, de Groot JWB, Haj Mohammad N, Homs MYV, van Laarhoven HWM, Molenaar IQ, Ten Tije BJ, de Vos-Geelen J, Besselink MG, van der Geest LGM, Wilmink JW, Dutch Pancreatic Cancer Group.
    Acta Oncol; 2020 Jun 01; 59(6):705-712. PubMed ID: 32056483
    [Abstract] [Full Text] [Related]

  • 18. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
    van Eijck CWF, de Koning W, van der Sijde F, Moskie M, Groot Koerkamp B, Homs MYV, van der Burg SH, van Eijck CHJ, Mustafa DAM.
    Eur J Cancer; 2023 Mar 01; 181():119-134. PubMed ID: 36652890
    [Abstract] [Full Text] [Related]

  • 19. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
    Karasek P, Gablo N, Hlavsa J, Kiss I, Vychytilova-Faltejskova P, Hermanova M, Kala Z, Slaby O, Prochazka V.
    Cancer Genomics Proteomics; 2018 Mar 01; 15(4):321-327. PubMed ID: 29976637
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma.
    O'Leary BR, Ruppenkamp EK, Steers GJ, Du J, Carroll RS, Wagner BA, Buettner GR, Cullen JJ.
    Pancreas; 2022 Jul 01; 51(6):684-693. PubMed ID: 36099493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.